Funding Details
- Awarder
- Inbox
- Date Award
- April 29, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Founding Year
- 2023
- Founders
- Atlas Venture
- Company Description
- Judo Bio has discovered a novel approach to create oligonucleotide medicines targeted to the kidney, an organ that has been challenging to access for genetic medicines. The company has completed preclinical studies successfully demonstrating receptor-mediated delivery of oligonucleotides to the kidney with proprietary ligand-siRNA conjugates that silence multiple target genes.
- Market
- Genetic Medicines
- Location
-
Cambridge,
MA,
US
- Coinvestors
- The Column Group, TCG, Droia Ventures, Digitalis Ventures, Euclidean Capital, Alexandria Venture Investments, YK Bioventures, and other undisclosed funds
Links